Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, 18 to 60 years of age, active duty military, retired military or other DOD beneficiaries eligible for care at military treatment facilities.~* Written informed consent and written authorization for use or release of health and research study information.~* Clear history of an identifiable muscle strain or trauma preceding the onset of low back pain.~* No prior history of vertebral disk disease/condition, sciatica or radiculopathy.~* Normal neurological examination without evidence of radiculopathy.~* Evidence of trigger point tenderness or muscle spasm upon palpation or EMG findings of muscle spasm.~* History of low back pain lasting 3 to 6 weeks from the time of injury or strain.~* VAS score minimum of 5 cm at time of entry into study.~* Ability to follow study instructions and likely to complete all required visits.~* Negative urine pregnancy test prior to the administration of study medication (for females of childbearing potential) (if applicable).~Exclusion Criteria:~* Age less than 18 or greater than 60.~* Not active duty.~* Concomitant use of aminoglycoside antibiotics, curare-like agents, or other agents that might interfere with neuromuscular function.~* Any medical condition that may put the subject at increased risk with exposure to Myobloc®, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis/motor neuron disease, neuropathy, renal stones, or any other disorder that might interfere with neuromuscular function or produce a similar type of low back pain.~* Females who are pregnant, breast-feeding, or planning a pregnancy during the study, or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.~* Known allergy or sensitivity to any of the components in the study medication.~* Evidence of alcohol or substance abuse in 6 months prior to enrollment.~* Systemic medical conditions (such as thyroid disease, hypertension, bleeding disorders, diabetes, cancers, etc.) that are not currently medically managed or controlled.~* Concurrent participation in another investigational drug or device study or participation in the 30 days immediately prior to study enrollment.~* Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.~* Significant Axis I or II diagnosis determined by a neurologist or psychiatrist in the 6 months prior to entry into the study.~* Duration of low back pain \< 3 weeks or \> 6 weeks.~* Thoracic or cervical spine pain in the absence of acute low back pain.~* Anesthetic or corticosteroid injection to the lumbosacral spine within 8 weeks of enrollment.~* Spine MRI (any region) positive for acute pathology or evidence of radiculopathy on neurological examination.~* History of back surgery within one year or incomplete resolution of back pain due to a previous injury or surgery.~* Subjects involved in litigation, seeking significant disability for low back pain, or with evident secondary gain as determined by the neurologist through chart review and subject interview.~* Any previous use of Myobloc®, Dysport®, or BOTOX®.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Botulinum Toxin B
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).